• Br J Anaesth · Mar 2024

    Editorial

    Under-dosing and over-dosing of neuromuscular blocking drugs and reversal agents: beware of the risks.

    • Jennifer M Hunter and Manfred Blobner.
    • Department of Musculoskeletal and Ageing Science, University of Liverpool, Liverpool, UK. Electronic address: bja@liverpool.ac.uk.
    • Br J Anaesth. 2024 Mar 1; 132 (3): 461465461-465.

    AbstractThe phenomena of residual curarisation and recurarisation after the use of long-acting non-depolarising neuromuscular blocking drugs such as tubocurarine and pancuronium were well recognised 60 years ago. But the incidence seemed to decline with the introduction of atracurium and vecuronium. However, recently there have been an increasing number of reports of residual and recurrent neuromuscular block. Some of these reports are a result of inappropriate doses of rocuronium, sugammadex or both, together with inadequate neuromuscular monitoring. We urge clinicians to review their practice to ensure the highest standards of clinical care when using neuromuscular blocking drugs and reversal agents. This includes the use of quantitative neuromuscular monitoring whenever neuromuscular blocking drugs are administered.Copyright © 2023 British Journal of Anaesthesia. Published by Elsevier Ltd. All rights reserved.

      Pubmed     Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        

    hide…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.

We guarantee your privacy. Your email address will not be shared.